Drug-labels.com Rechercher Menu

ASA EC : monographie de produit

La monographie de produit s’adresse aux professionnels de la santé. Les patients trouveront des explications en langage clair dans les renseignements pour les patients: grossesse et allaitement.

Statut:
En vente libre État actuel: Dormant Données
Concentration:
81 mg
Ingrédient actif:

Monographie de produit - ASA EC

RÉFÉRENCES

Abbatiello ER KM, Weisbroth S. The effect of prostaglandins and prostaglandin inhibitors on spermatogenesis. International Journal of Fertility. 1975;20(3): 177-82.

Abbott F, Kassam J, Orr J, and K. Farrell. The effects of ASPIRIN on valproic acid metabolism. Clin. Pharmacol. Ther. 1986; 40:94-100.

Ali NAJ, Al-Naama LM, Khalid LO. Haemolytic potential of three chemotherapeutic agents and ASPIRIN in glucose-6-phosphate dehydrogenase deficiency. East Mediterr Health J. 1999 May; 5(3):457-64.

Altman R, Boullon F, Rouvier J, Raca R, de la Fuente, Favaloro R. ASPIRIN and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976; 72: 127-9.

Amrein PC, Ellman L, Harris WH. ASPIRIN prolongation of bleeding time and perioperative blood loss. JAMA 1981; 245: 1825-8.

Analgesic-antipyretic and anti-inflammatory agents: the salicylates. In: Goodman and Gilman’s, The Pharmacological Basis of Therapeutics, 9th Edition, Hardman JG, Limbird LE, Gilman (eds), McGraw- Hill, USA, 1996.

Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.

Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994; 308: 158- 68.

Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994; 308:235-46.

Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-31.

Antonucci R, Zaffanello M, Puxeddu E, Porcella A, Cuzzolin L, Pilloni , Fanos V. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012 May 1; 13(4):474-90.

Anzellotti P et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum. 2011;63:850-859.

Asok Kumar R CN. Effects of acetylsalicylic acid on reproductive organs of adolescent male rats. Endocrinologia Experimentalis. 1988;22(3):187-95.

ASPIRIN Myocardial Infarction Study Research Group. A randomized controlled trial of ASPIRIN in persons recovered from myocardial infarction. JAMA 1980; 243: 661-9.

ASPIRIN Myocardial Infarction Study Research Group: The ASPIRIN myocardial infarction study: final results. Circulation 1980; 62 (Suppl V): V79-V84.

Bailey JM. Prostacyclins, thromboxane and cardiovascular disease. Tr Biochem Sci 1979; 4: 68- 71. Baxster, K. Stockley’s Drug Interactions, 9 Edition. Royal Pharmaceutical Society, 2010; 1123, 1135-1136.

Baxster, K. Stockley’s Drug Interactions, 9 Edition. Royal Pharmaceutical Society, 2010; 1123, 1135-1136.

Boston Collaborative Drug Surveillance Group. Regular ASPIRIN intake and acute myocardial infarction. Br Med J 1974; 1: 440-3.

Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, et al. "AICLA" controlled trial of ASPIRIN and dipyridamole in the secondary prevention of athero_thrombotic cerebral ischema. Stroke 1983; 14:5-14.

Boyd EM. Analgesic abuse. Maximal tolerated daily doses of acetylsalicylic acid. Can Med Assoc J 1968; 99: 790-8.

Boyd EM. The acute oral toxicity of acetylsalicylic acid. Toxic Appl Pharmac 1959; 1: 229-39.

Breddin K, Loew D, Lechner K, Oberla K, Walter E. The German_Austrian trial. A comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation 1980; 62 (Suppl V): V63-V72.

Breddin K, Loew D, Lechner K, Uberla K, Walter E. Secondary prevention of myocardial infarction: Comparison of treatment with acetylsalicylic acid, phenprocoumon or placebo. A multicentre 2 year prospective study. Int Congr Ser 1979; 470: 263-8.

Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, et al. ASPIRIN, sulfinpyrazone, or bothin unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369-75.

Canadian Cooperative Study Group. A randomized trial of ASPIRIN and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299: 53-9.

Capone M et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005; 45 (8): 1295-30.

Casey RG, Tan M, Ryan J, Gillen P. Nonsteroidal anti-inflammatory induced small bowel obstruction. Irish journal of medical science. 2002;171(2):118.

Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Was SN, Fitzgerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001 Dec 20;345(25):1809-17.

Cenedella RJ CW. Effect of aspirin upon male mouse fertility. Prostaglandins. 1973;4(2):285-90.

Chen WC, Lin KH, Huang YT, Tsai TJ, Sun WC, Chuah SK, et al. The risk of lower gastrointestinal bleeding in low-dose aspirin users. Alimentary pharmacology & therapeutics. 2017;45(12):1542-50.

Chernolesskiy A, Lanzon-Miller S, Hill F, Al-Mishlab T, Thway Y. Subacute small bowel obstruction due to diaphragm disease. Clinical medicine. 2010;10(3):296-8.

Christopher J. Needs and Peter M. Brooks. Clinical Pharmacokinetics of the Salicylates. Clinical Pharmacokinetics 1985 10: 164-177.

Clark DA BD, Chaouat G. Effect of prostaglandin synthesis inhibitors on spontaneous and endotoxin-induced abortion in mice. Journal of Reproductive Immunology. 1993;24(1):29-44.

Clive DM, Stoff JS. Renal syndromes associated with non-steroidal anti-inflammatory use. N Engl J Med. 1984 Mar 1; 310(9):563-72.

Clopath P. The effect of acetylsalicylic acid (ASA) on the development of atherosclerotic lesions in miniature swine. Br J Exp Path 1980; 61: 440-3.

Conte D NM, Fillo S, De Giorgio G, Isidori A, Romanelli F. Aspirin inhibition of naloxone-induced luteinizing hormone secretion in man. Journal of Clinical Endocrinology and Metabolism. 1996;81(5):1772-5.

Conte D RF, Fillo S, Guidetti L, Isidori A, Franceschi F, et al. Aspirin inhibits androgen response to chorionic gonadotropin in humans. American Journal of Physiology - Endocrinology and Metabolism. 1999;277(6):1032-7.

Coronary Drug Project Research Group. ASPIRIN in coronary heart disease. J Chron Dis 1976; 29: 625- 42.

Coronary Drug Project Research Group. ASPIRIN in coronary heart disease. Circulation 1980; 62 (Suppl V): V59-V62.

Cortina G, Wren S, Armstrong B, Lewin K, Fajardo L. Clinical and pathologic overlap in nonsteroidal anti-inflammatory drug-related small bowel diaphragm disease and the neuromuscular and vascular hamartoma of the small bowel. The American journal of surgical pathology. 1999;23(11):1414-7.

Craven LL. Acetylsalicylic acid, Possible preventive coronary thrombosis. Ann West Med Surg 1950; 4: 95-9.

Craven LL. Prevention of coronary and cerebral thrombosis. Miss Valley Med J 1956; 78: 213-5.

Cryer B, Berlin RG, Cooper SA, et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther 2005;27(2):185-91.

Czaplicki S, Gietka J, Suzek K. The frequency of coronary heart disease and myocardial infarction in rheumatoid arthritis patients. Cor Vasa 1978; 20: 249-54.

Dalton SO, Johansen C, Mellemkjoer L, Nøgård B, Sørsen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a populationbased cohort study. Arch Intern Med. 2003 Jan 13; 163(1):59-64.

Danese CA, Voletti CD, Weiss HJ. Protection by ASPIRIN against experimentally induced arterial thrombosis in dogs. Thrombos Diathes Haemorrh 1971; 25: 288-96.

Danial AK, Al-Mouakeh A, Danial YK, Nawlo AA, Khalil A, Al-Haj A. A rare cause of small bowel diaphragm disease presenting with palpated abdominal mass. Journal of surgical case reports. 2019;2019(8):rjz230.

Dargan PI, Wallace CI, and Jones AL. An evidence based flowchart to guide the management of acute salicylate (ASPIRIN) overdose. Emer Med J 2002; 19:206-209.

De Caterina R, Giannessi D, Boem A, Bernini W, Battaglia D, Michelassi C, Dell’Amico F, L’Abbate A, Patrignani P, Patrono C. Equal antiplatelet effects of ASPIRIN 50 or 324 mg/day in patients after acute myocardial infarction. Thromb Haemostas 1985; 54: 528-32.

De Gaetano G. Primary prevention of vascular disease by ASPIRIN. Lancet 1988; 1: 1093- 1094.

De Petris G, López J. Histopathology of diaphragm disease of the small intestine: a study of 10 cases from a single institution. Am J Clin Pathol. 2008;Oct;130(4):518-25.

Dentali F, Ageno W, Rezoagli E, Rancan E, Squizzato A, Middeldorp S, et al. Low-dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta-analysis of the literature. Journal of thrombosis and haemostasis: JTH. 2012;10(10):2075-85.

De Swiet M, Fryers G. Review: the use of ASPIRIN in pregnancy. J Obstet Gynecol. 1990; 10:467- 482.

Didolkar AK GA, Joshi UM, Sheth AR, Roychowdhury D. Effects of aspirin on blood plasma levels of testosterone, LH and FSH in maturing male rats. International Journal of Andrology. 1980;3(3):312-8.

Di Luigi L, Rossi C, Sgro P, Fierro V, Romanelli F, Baldari C, et al. Do non-steroidal anti-inflammatory drugs influence the steroid hormone milieu in male athletes? International journal of sports medicine. 2007;28(10):809-14.

Dunn MJ, Scharschmidt L, Zambraski E. Mechanisms of nephrotoxicity of non-steroidal anti- inflammatory drugs. Arch Toxicol Suppl. 1984; 7:328-37.

Dunn MJ, Zambraski EJ. Renal effects of drugs that inhibit prostaglandin synthesis. Kidney Int. 1980 Nov; 18(5):609-622.

Editorial. ASPIRIN after myocardial infarction. Lancet 1980; 1: 1172-3.

Editorial. Trials of drugs for prevention of 'secondary' MIs indecisive. Hosp Prac (April) 1980: 53-4.

Ellershaw JE, Kelly MJ. Corticosteroids and peptic ulceration. Palliative medicine. 1994;8(4):313-9.

Elwood PC, Sweetnam PM. ASPIRIN and secondary mortality after myocardial infarction. Lancet 1979; 2: 1313-5.Ekaluo UB IE, Udokpoh AE. Sperm head abnormality and mutagenic effects of aspirin, paracetamol and caffeine containing analgesics in rats. Internet Journal of Toxicology. 2010;7(1).

Emami NH, Lafout FM, Mohammadghasemi F. Administration of melatonin protects against acetylsalicylic acid-induced impairment of male reproductive function in mice. Iranian journal of basic medical sciences. 2018;21(2):124-9.

Evans M, Fored CM, Bellocco R, Fitzmaurice G, Fryzek JP, McLaughlin JK, Nyrén O, Elinder CG. Acetaminophen, ASPIRIN and progression of advanced chronic kidney disease. Nephrol Dial Transplant. 2009 Jun; 24(6):1908-18.

Farah AE, Rosenberg F. Potential therapeutic application of ASPIRIN and othercyclo- oxygenase inhibitors. Br J Clin Pharmac 1980; 10: 261S-78S.

Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of ASPIRIN in cerebral ischemia. Stroke 1977; 8: 301-16.

Fitzgerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA and Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of ASPIRIN in man. Clin Invest 1983; 71: 676-88.

Flower RJ, Moncada S, Vane JR. Analgesic _ antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout. In: The Pharmacological Basis of Therapeutics, Chapter 29, 1980, 682-692.

Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, Lipworth L, Elinder CG, Blot WJ, McLaughlin JK, Zack MM, Nyrén O. Acetaminophen, ASPIRIN, and chronic renal failure. N Engl J Med. 2001 Dec 20; 345(25):1801-8.

Frattarelli JL, McWilliams GDE, Hill MJ, Miller KA, Scott RT, Jr. Low-dose aspirin use does not improve in vitro fertilization outcomes in poor responders. Fertility and sterility. 2008;89(5):1113-7.

Garcia Rodriguez LA, Lin KJ, Hernandez-Diaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogre l and other medications. Circulation. 2011;123(10):1108-15.

Gargot D, Chaussade S, d'Alteroche L, Desbazeille F, Grandjouan S, Louvel A, et al. Nonsteroidal anti-inflammatory drug-induced colonic strictures: two cases and literature review. The American journal of gastroenterology. 1995;90(11):2035-8.

Genton E. A perspective on platelet - suppressant drug treatment in coronary artery and cerebrovascular disease. Circulation 1980; 62: V111-V121.

Glader BE. Evaluation of the hemolytic role of ASPIRIN in glucose-6-phosphate dehydrogenase deficiency. J Pediatri. 1976 Dec; 89(6):1027-8.

Green LH, Seroppian E, Handin RI. Platelet activation during exercise-inducedmyocardial ischemia. N Engl J Med 1980; 302: 193-7.

Groeneveld E, Broeze KA, Lambers MJ, Haapsamo M, Dirckx K, Schoot BC, et al. Is aspirin effective in women undergoing in vitro fertilization (IVF)? Results from an individual patient data meta-analysis (IPD MA). Human reproduction update. 2011;17(4):501-9.

Grosser N, Schröder H. ASPIRIN protects endothelial cells from oxidant damage via thenitric oxide- cGMP pathway. Arterioscler Thromb Vasc Biol. 2003 Aug 1; 23(8):1345-51. Epub 2003 Jun 26.

Grosser N, Abate A, Oberle S, Vreman HJ, Dennery PA, Becker JC, Pohle T, Seidman DS, Schröder H. Heme oxygenase-1 induction may explain the antioxidant profile of Aspirin. Biochem Biophys Res Commun. 2003 Sep 5;308(4):956-60.

Guslandi M. Gastric toxicity of antiplatelet therapy with low-dose ASPIRIN. Drugs 1997; 53: 1- 5.

Haddad LM et al. Clinical Management of Poisoning and Drug Overdose 3rd ed. Chap 50, Salicylate Toxicity. W.B. Saunders Company ©1998, p. 675-687.

Haft JI. Platelets and coronary artery disease. Prim Card 1979; June: 97-104.

Halter F, Gut A, Ruchti C. Intestinal pathology from NSAIDs. Inflammopharmacology. 1996;4, 43–60

Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, and Westerling S. Effects of intensive blood-pressure lowering and low-dose ASPIRIN in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 Jun 13; 351(9118):1755-62.

Harker LA, Slichter SJ. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med 1970; 283: 1302-5.

Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, Baum S, De Sanctis RW. ASPIRIN prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med 1977: 297: 1246-9.

Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, Baum S, De Sanctis RW. Comparison of warfarin, low molecular_weight dextran, ASPIRIN and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement. J Bone Joint Surg 1974; 56: 1552-62.

Harrison MJG, Marshall J, Meadows JC, Russell RWR. Effect of ASPIRIN in Amaurosis Fugax. Lancet 1971; 2: 743-4.

Hayashi Y, Yamamoto H, Taguchi H, Sunada K, Miyata T, Yano T, et al. Nonsteroidal anti-inflammatory drug-induced small-bowel lesions identified by double-balloon endoscopy: endoscopic features of the lesions and endoscopic treatments for diaphragm disease. Journal of gastroenterology. 2009;44 Suppl 19:57-63.

Hennekens CH, Peto R, Hutchison GB, Doll R. An overview of the British and American ASPIRIN studies. N Engl J Med 1988; 318:923-4.

Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. ASPIRIN and other platelet-active drugs. The relationship between dose, effectiveness and side effects. Chest 1992; 102:327S-36S.

Hoffman W, Forster W. Two year Cottbus reinfarction study with 30 mg ASA per day. Prostaglandins, Leukotrienes and Essential Fatty Acid 1991; 44: 159-69.

Hoffman W, Nitschke M, Muche J, Kampe W, Handreg W, Forster W. Reevaluation of the Cottbus reinfarction study with 30 mg ASPIRIN per day 4 years after the end of thestudy. Prostaglandins, Leukotrienes and Essential Fatty Acids 1991; 42: 137-9.

Hogben AMC, Tocco DJ, Brodie BB, Schanker LS. On the mechanism of intestinal absorption of drugs. J Pharm Ther 1959; 125: 275-82.

Hollifield, JW. Failure of ASPIRIN to Antagonize the Antihypertensive Effect of Spironolactone in Low- Renin Hypertension. Southern Medical Journal 1976; 69(8): 1034-

1036.

Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM for the Heparin- ASPIRIN Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose ASPIRIN as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323: 1433-7.

Hsieh YY TH, Chang CC, Lo HY, Chen CL. Low-dose aspirin for infertile women with thin endometrium receiving intrauterine insemination: A prospective, randomized study. Journal of Assisted Reproduction and Genetics. 2000;17(3):174-7.

Hume M, Bierbaum B, Kurlakose TX, Surprenant J. Prevention of post_operative thrombosis by ASPIRIN. Amer J Surg 1977; 133: 420-2.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral ASPIRIN, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988 Aug13;2(8607):349-60.

Jakubowski JA, Stampfer MJ, Vaillancourt R, Deykin D. Cumulative antiplatelet effect of lowdose enteric coated ASPIRIN. Br J Haematol 1985; 60: 635-42.

James MJ, Walsh JA. Effects of ASPIRIN and alcohol on platelet thromboxane synthesis and vascular prostacyclin synthesis. Thromb Res. 1985 Sep 1; 39(5):587-93.

Jennings JJ, Harris WH, Sarmiento A. A clinical evaluation of ASPIRIN prophylaxis of thromboembolic disease after total hip arthroplasty. J Bone Joint Surg 1976; 58: 926-8.

Jonnalagadda S, Prakash C. Intestinal strictures can impede wireless capsule enteroscopy. Gastrointestinal endoscopy. 2003;57(3):418-20.

Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R, for the Swedish Angina Pectoris ASPIRIN Trial (SAPAT) Group: Double-blind trial of ASPIRIN in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421-5.

Kaufman DW, Kelly JP, Wiholm BE, Laszlo A, Sheehan JE, Koff RS, Shapiro S. The risk of acute major upper gastrointestinal bleeding among users of ASPIRIN and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol. 1999 Nov; 94(11):3189-3196.

Kelly ME, McMahon LE, Jaroszewski DE, Yousfi MM, De Petris G, Swain JM. Small- bowel diaphragm disease: seven surgical cases. Archives of surgery. 2005;140(12):1162- 6.

Koomanan N, Ko Y, Yong W, Ng R, Wong Y, Lim S, et al. Clinical Impact of Drug– Drug Interaction Between Aspirin and Prednisolone at a Cancer Center. Clinical Therapeutics. 2012;Volume 34(Issue 12).

Kumpuris AG, Luchi RJ, Waddell CC, Miller RR. Production of circulating platelet aggregates by exercise in coronary patients. Circulation 1980; 61: 62-5.

Kurth T, Glynn RJ, Walker AM, Rexrode KM, Buring JE, Stampfer MJ, Hennekens CH, Gaziano JM. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis. 2003 Aug; 42(2):234-44.

Lang J, Price AB, Levi AJ, Burke M, Gumpel JM, Bjarnason I. Diaphragm disease: pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drugs. Journal of clinical pathology. 1988;41(5):516-26.

Levi S, de Lacey G, Price AB, Gumpel MJ, Levi AJ, Bjarnason I. "Diaphragm-like" strictures of the small bowel in patients treated with non-steroidal anti-inflammatory drugs. The British journal of radiology. 1990;63(747):186-9.

Levin A, Stevens L, McCullough PA. Cardiovascular disease and the kidney: tracking a killerin chronic kidney disease. Postgrad Med. 2002 Apr; 111(4):53-60.

Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial. 2003 Mar-Apr;16(2):101-5.

Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, et al. Protective effects of ASPIRIN against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403.

Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN. Aspirin is efficacious for the treatment of acute migraine. Headache. 2005 Apr;45(4):283-92.

Lindblad B, et al. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery?A double- blind, placebo-controlled randomized trial. Stroke 1993; 24:1125-8.

Luo PJ, Lin XH, Lin CC, Luo JC, Hu HY, Ting PH, et al. Risk factors for upper gastrointestinal bleeding among aspirin users: An old issue with new findings from a population-based cohort study. Journal of the Formosan Medical Association = Taiwan yi zhi. 2019;118(5):939-44.

MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of ASPIRIN. Lancet. 2003 Feb 15; 361(9357):573-4.

Malseed R, Malseed Z. ASPIRIN: a pharmacologic profile. Amer J Pharm 1978; July-Aug: 150: 99-106.Mangano DT. ASPIRIN and mortality from coronary bypass surgery. N Engl J Med. 2002 Oct 24; 347(17):1309-17.

Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002 Oct 24;347(17):1309-17.

Masclee GM, Valkhoff VE, Coloma PM, de Ridder M, Romio S, Schuemie MJ, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014;147(4):784-92 e9; quiz e13-4.

McCann RL, Hagen P, Fuchs JCA. ASPIRIN and dipyridamole decrease intimal hyperplasia in experimental vein grafts. Ann Surg 1980; 191: 238-43.

McInerney KA, Hatch EE, Wesselink AK, Rothman KJ, Mikkelsen EM, Wise LA. Preconception use of pain-relievers and time-to-pregnancy: a prospective cohort study. Human reproduction. 2017;32(1):103-11.

McKenna R, Bachmann F, Kaushal SP, Galante JO. Thromboembolic disease in patients undergoing total knee replacement. J Bone Joint Surg 1976; 58: 928-32.

Medical Research Council’s General Practice Research Framework. Thrombosis prevention trial:randomized trial of low-intensity oral anticoagulation with warfarin and low-dose ASPIRIN in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998:351:233-41.

Meek IL, Vonkeman HE, Kasemier J, Movig KL, van de Laar MA. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013;69:365-71.

Mehta J, Mehta P, Burger C, Pepine CJ. Platelet function studies in coronary heart disease. IV. Effect of ASPIRIN. Atherosclerosis 1978; 31: 169-75.

Mehta J, Mehta P, Pepine CJ, Contic CR. Platelet aggregation studies in coronary heart disease. VII. Effect of ASPIRIN and tachycardia stress on aortic and coronary venous blood. Am J Cardiol 1980; 45: 945-51.

Mehta P, Mehta J. Platelet function studies in coronary heart disease. V. Evidence for enhanced platelet microthrombus formation activity in acute myocardial infarction. Am J Cardiol 1979; 43: 757-60.

Mirande MD, Mirande RA. Management of a postbulbar duodenal ulcer and stricture causing gastric outlet obstruction: A case report. Annals of medicine and surgery. 2018;29:10-3.

Monahan DW, Starnes EC, Parker AL. Colonic strictures in a patient on long-term non- steroidal anti-inflammatory drugs. Gastrointestinal endoscopy. 1992;38(3):385-8.

Montgomery PR, Berger LG, Mitenko PA, Sitar DS. Salicylate metabolism: effects of age and sex in adults. Clin Pharmacol Ther. 1986 May;39(5):571-6.

Morley J. Mechanism of action of ASPIRIN in inflammation. Proc Roy Soc Med 1977; 70: 32-6.

Moschos CB, Haider B, De La Cruz C, Lyons MM, Regan TJ. Antiarrhythmic effects of ASPIRIN during non_thrombotic coronary occlusion. Circulation 1978; 57:681-4.

Mundall J, Quintero P, Von Kaulla KN, Harmon R, Austin J. Transient monocular blindness and increased platelet aggregability treated with ASA. Neurology 1972; 22: 280-5.

Munipalle PC, Garud T, Light D. Diaphragmatic disease of the colon: systematic review. Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland. 2013;15(9):1063-9.

Murray , Black PK, Kuzmik DD, Haag KM, Manatunga AK, Mullin MA, Hall SD, Brater DC. Acute and chronic effects of nonsteroidal antiinflammatory drugs on glomerular filtration rate in elderly patients. Am J Med Sci. 1995 Nov; 310(5):188-97.

Murray , Brater DC. Effects of NSAIDS on the kidney. Prog Drug Res. 1997; 49:155-71.

Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. Journal of basic and clinical pharmacy. 2016;7(2):27-31.

Nobles CJ, Mendola P, Mumford SL, Kim K, Sjaarda L, Hill M, et al. Metabolic Syndrome and the Effectiveness of Low-dose Aspirin on Reproductive Outcomes. Epidemiology. 2019;30(4):573-81.

Noor MT, Dixit P, Kochhar R, Nagi B, Dutta U, Singh K, et al. NSAIDs-Related Pyloroduodenal Obstruction and Its Endoscopic Management. Diagnostic and therapeutic endoscopy 2011;2011:967957.

Oldenhof J, Hochberg M, Schiff M, Brune K. Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B2. Curr.

Med. Res. Opin. 2010; 26 (6): 1497-1504

Orme Orme M. ASPIRIN all round? Br Med J 1988; 296:307-8.

Orr J, Abbott F, Farrell K, Ferguson S, Sheppard I, and W Godolphin, Interaction between valproic acid and ASPIRIN in epileptic children: Serum protein binding and metabolic effects. Clin. Pharmacol.Ther. 1982:31:642-649.

Oyedeji KO BA, Adigun AK. Effect of aspirin on reproductive functions in male Albino rats. Research Journal of Pharmacology. 2013;7(2):16-20.

Packham MA, Mustard JF. Pharmacology of platelet affecting drugs. Circulation 1980; 62: V26- V41.

Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose ASPIRIN in healthy subjects. J Clin Invest 1982; 69: 1366-72.

Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davì G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72:1177-84.

Penner RM, Williams CN. Resolution of multiple severe nonsteroidal anti-inflammatory drug-induced colonic strictures with prednisone therapy: a case report and review of the literature. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2003;17(8):497-500.

Persantine_ASPIRIN Reinfarction Study (PARIS) Research Group: The Persantine ASPIRIN reinfarction study. Circulation 1980; 62 (Suppl V): V85-V88.

Pick R, Chediak J, Glick G. ASPIRIN inhibits development of coronary atherosclerosis in cynomolgusmonkeys (Macaca Fascicularis) fed on atherogenic diet. J Clin Invest 1970; 63: 158- 62.

Pugliese F, Ciabattoni G. The role of prostaglandins in the control of renal function: renal effects of nonsteroidal anti-inflammatory drugs. Clin Exp Rheumatol. 1984 Oct-Dec;2(4):345-52.

Rao GH, Johnson GG, Reddy KR, White JG. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis. 1983;3:383-388.

Relman AS. ASPIRIN for the primary prevention of myocardial infarction. N Engl J Med1988; 318: 245- 6.

Renaud S, Godu J. Thrombosis prevention by acetylsalicylic acid in hyperlipemic rats. CMAJ 1970: 103; 1037-40.

RISC Group. Risk of myocardial infarction and death during treatment with low dose ASPIRIN and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30.

Roberts MS, Joyce RM, McLeod LJ, Vial JH, Seville PR. Slow-release ASPIRIN and prostaglandin inhibition. Lancet 1986; 1(8490): 1153-4.

Robinson MH, Wheatley T, Leach IH. Nonsteroidal antiinflammatory drug-induced colonic stricture. An unusual cause of large bowel obstruction and perforation. Digestive diseases and sciences. 1995;40(2):315-9.

Ross R, Glomset JA. Pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 369_377, 420-5.

Roth GJ, Stanford N, Majenus PW. Acetylation of prostaglandin synthase by ASPIRIN. ProcNat Acad Sci 1975; 72: 3073-6.

Rowland M, Riegelman S. Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man. J Pharm Sci 1968; 57: 1313-9.

SALT Collaborative Group. Swedish ASPIRIN Low-Dose Trial (SALT) of 75 mg ASPIRINas secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345-9.

Salzman EW, Harris WH, De Sanctis RW. Reduction in venous thromboembolism by agents affecting platelet function. N Engl J Med 1971; 284: 1287-92.

Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000 Apr; 35(4 Suppl 1): S117-31.

Schafer A, Handin R. The role of platelets in thrombotic and vascular disease. Proj Cardio Dis 1979; 22: 31-52.

Schisterman EF, Mumford SL, Schliep KC, Sjaarda LA, Stanford JB, Lesher LL, et al. Preconception low dose aspirin and time to pregnancy: findings from the effects of aspirin in gestation and reproduction randomized trial. The Journal of clinical endocrinology and metabolism. 2015;100(5):1785-91.

Schrör K. Acetylsalicylic acid. Chapter 3 Toxicity and Drug Safety: Section 3.2.2.2 Mode of ASPIRIN Action; WILEY-VCH Verlag GmbH & Co. KGaA Weinheim 2009; 180-181.

Scott JE PT. A quantitative study of the effects of acetylsalicylic acid on spermatogenesis and organs of the rat. International Journal of Fertility. 1978;23(4):282-7.

Shahidi NT, Westring DW. Acetylsalicylic acid-induced hemolysis and its mechanism. J Clin Invest. 1970 Jul; 49(7):1334-40.

Shalev O. Long-term, low-dose ASPIRIN is safe in glucose-6-phosphate dehydrogenase deficiency. DICP. 1991 Oct; 25(10):1074-75.

Shirlow R HM, Volovsky M, MacLachlan V, Vollenhoven B. The effects of adjuvant therapies on embryo transfer success. Journal of Reproduction and Infertility. 2017;18(4):368-78.

Sjaarda LA, Radin RG, Silver RM, Mitchell E, Mumford SL, Wilcox B, et al. Preconception Low-Dose Aspirin Restores Diminished Pregnancy and Live Birth Rates in Women With Low-Grade Inflammation: A Secondary Analysis of a Randomized Trial. The Journal of clinical endocrinologyand metabolism. 2017;102(5):1495-504.

Slesser AA, Wharton R, Smith GV, Buchanan GN. Systematic review of small bowel diaphragm disease requiring surgery. Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland. 2012;14(7):804-13.

Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. ASPIRIN and congenital malformations. Lancet. 1976 Jun 26; 1(7974):1373-5.

Smith MJH. Plasma_salicylate concentrations after small doses of acetylsalicylic acid. J Pharm Pharmacol 1951; 3: 409-14.

Soreff J, Johnson H, Diener L, Göransson L. Acetylsalicylic acid in a trial to diminish thromboembolic complications after elective hip surgery. Acta Orthop Scand 1975; 46: 246-55.

Spirnak JP, Monahan DW. Colonic diaphragms associated with long-term use of nonsteroidal antiinflammatory drugs. AJR American journal of roentgenology. 1993;160(5):1148-9.

Spiro HM, Milles SS. Clinical and physiologic implications of the steroid-induced peptic ulcer. The New England journal of medicine. 1960;263:286-94.

Steering Committee of the Physicians’ Health Study Research Group. Final report on the ASPIRIN component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med. 1989 Jul 20; 321(3):129-35.

Stockman III JA, Lubin B, Oski FA. ASPIRIN-induced hemolysis: the role of concomitant oxidant (H2O2) challenge. Pediatr Res. 1978 Sept; 12(9):927-31.

Stutz G ZJ, Santillán ME, Vincenti L, De Cuneo MF, Ruiz RD. The effect of alcohol, tobacco, and aspirin consumption on seminal quality among healthy young men. Archives of Environmental Health. 2004;59(11):548-52.

Tamura I, Fujita T, Tsumura H, Morita Y, Yoshida M, Toyonaga T, et al. Low-dose aspirin-induced gastroduodenal mucosal injury in Japanese patients with arteriosclerotic disease. Internal medicine. 2010;49(23):2537-45.

Tata LJ, Fortun PJ, Hubbard RB, Smeeth L, Hawkey CJ, Smiths CJP, Whitaker HJ, Farrington CP, Card TR, West J. Does concurrent prescription of selective serotonin reuptake inhibitorsand non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther. 2005 Aug 1; 22(3):175-81.

The Dutch TIA Trial Study Group. A comparison of two doses of ASPIRIN (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325: 1261-6.

UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) ASPIRIN trial: interim results. Br Med J 1988; 296: 316-20.

USFDA-CDER. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers 2005.

Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for ASPIRIN-like drugs. Nature New Biol 1971; 231: 232-5.

Verheugt FWA, van der Loarse A, Funke-Kupper AJ, Sterkman LGW, Galema TW, Roos JP. Effects of early intervention with low-dose ASPIRIN (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990; 66: 267-70.

Wallentin LC and The Research Group on Instability in Coronary Artery Disease in Southeast Sweden. ASPIRIN (75 mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol 1991; 18: 1587-93.

Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968; 47: 2169-80.

Weiss HJ. Antiplatelet therapy (second of two parts). N Engl J Med 1978; 298: 1403-6.

Wessinger S, Kaplan M, Choi L, Williams M, Lau C, Sharp L, Crowell , Keshavarzian A, Jones MP. Increased use of selective serotonic reuptake inhibitors in patients admitted with gastrointestinal hemorrhage: a multicenter retrospective analysis. Alimet Pharmacol Ther. 2006 Apr 1; 23(7):934-44.

Wright HN. Chronic toxicity studies of analgesic and anti-pyretic drugs and congeners. Toxicol Appl Pharmacol 1967; 11: 280-92.

Young VP, Giles AR, Pater J, Corbett WE. Sex differences in bleeding time and blood loss in normal subjects following ASPIRIN ingestion. Thromb Research 1980; 20: 705-9.

Zambraski EJ, Dunn MJ. Renal effects of ASPIRIN 1992 Edited by Vane JR and Botting RM in: ASPIRIN and other salicylates. London-New York-Tokyo-Melbourne-Madras: Chapman & Hall Medical; 510-530.

Zuik M, Mandel MA. Methotrexate-salicylate interaction: a clinical and experimental study. Surg Forum. 1976; 26:567-9.

ASPIRIN Monographie de produit, Bayer Inc., Date of révision: 19 mai 2021, numéro de Control 248124.

À propos de ce document

Source: Santé Canada – Base de données sur les produits pharmaceutiques (BDPP) et monographies de produit · DIN (numéro d’identification du médicament): 02426811

Vous avez trouvé une erreur? Écrivez-nous à la page Nous joindre.

L’information présentée sur ce site ne remplace pas les conseils d’un médecin ou d’un pharmacien.

Information sur le médicament ASA EC

Sur ordonnance ou en vente libre
En vente libre?
DIN 02426811
Annexe(s) Médicaments sans ordonnance
Ingrédient(s) actif(s) Acide acétylsalicylique 81 MG
Forme(s) posologique(s) Comprimé (à libération retardée)
Voie(s) d’administration Orale
Classe de médicaments (ATC de l’OMS)
  1. B Sang et organes hématopoïétiques
    1. B01 Antithrombotiques
      1. B01A Antithrombotiques
        1. B01AC Inhibiteurs de l'agrégation plaquettaire, héparine exclue
          1. B01AC06 Acide acétylsalicylique
Entreprise SANIS HEALTH INC
État actuel Dormant
Date de l’état actuel 2025-11-06

Source: Santé Canada – Base de données sur les produits pharmaceutiques (BDPP) et monographies de produit, données en date du 2026-11-11. Données de la Base de données sur les produits pharmaceutiques de Santé Canada, telles que publiées. Ne remplace pas les conseils d’un médecin ou d’un pharmacien.